- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2024
- 197 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- July 2024
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- August 2024
- 117 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- May 2023
- 270 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- October 2023
- 173 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- June 2020
- 464 Pages
Global
From €4459EUR$4,900USD£3,823GBP
- Report
- May 2023
- 93 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2022
- 303 Pages
Global
From €3495EUR$3,840USD£2,996GBP
The Hereditary Cancer Testing market is a subset of the Diagnostics industry, focusing on the detection of genetic mutations that can lead to an increased risk of developing certain types of cancer. Tests are typically conducted on a patient's saliva or blood sample, and the results are used to inform decisions about preventative measures, such as increased screening or prophylactic surgery. Hereditary Cancer Testing is a rapidly growing field, with new technologies and tests being developed to detect more mutations and provide more accurate results.
Companies in the Hereditary Cancer Testing market include Ambry Genetics, Invitae, Myriad Genetics, Counsyl, and Color Genomics. Show Less Read more
